期刊
ONCOTARGET
卷 7, 期 50, 页码 81995-82012出版社
IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.13226
关键词
melanoma; BRAF; vemurafenib; PLX-4720; TGF-beta
资金
- CRUK Beatson Institute
- Worldwide Cancer Research [11-078]
- CRUK Manchester Institute [C5759/A12328]
- Wellcome Trust [100282/Z/12/Z]
- Cancer Genomics Centre, Netherlands
- Cancer Research UK [22902, 19279, 17240] Funding Source: researchfish
- Worldwide Cancer Research [11-0788] Funding Source: researchfish
Recent data implicate elevated transforming growth factor-beta (TGF beta) signalling in BRAF inhibitor drug-resistance mechanisms, but the potential for targeting TGF beta signalling in cases of advanced melanoma has not been investigated. We show that mutant BRAFV600E confers an intrinsic dependence on TGF beta/TGF beta receptor 1 (TGFBR1) signalling for clonogenicity of murine melanocytes. Pharmacological inhibition of the TGFBR1 blocked the clonogenicity of human mutant BRAF melanoma cells through SMAD4-independent inhibition of mitosis, and also inhibited metastasis in xenografted zebrafish. When investigating the therapeutic potential of combining inhibitors of mutant BRAF and TGFBR1, we noted that unexpectedly, low-dose PLX-4720 (a vemurafenib analogue) promoted proliferation of drug-naive melanoma cells. Pharmacological or pharmacogenetic inhibition of TGFBR1 blocked growth promotion and phosphorylation of SRC, which is frequently associated with vemurafenib-resistance mechanisms. Importantly, vemurafenib-resistant patient derived cells retained sensitivity to TGFBR1 inhibition, suggesting that TGFBR1 could be targeted therapeutically to combat the development of vemurafenib drug-resistance.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据